<DOC>
	<DOC>NCT00961766</DOC>
	<brief_summary>The primary objective of the study is to determine the safety/tolerability profile, systemic PK behavior, and immunogenicity of single IV and SC administrations of BG00010 to sciatica participants.</brief_summary>
	<brief_title>Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica Participants</brief_title>
	<detailed_description />
	<mesh_term>Sciatica</mesh_term>
	<criteria>Key Must have a diagnosis of unilateral sciatica, determined by the Investigator. Sciatica symptoms must be present for 6 or more weeks prior to the Screening Visit. Must have a body mass index (BMI) between 18 kg/m2 and 32 kg/m2. Must rate their pain at &gt;40 mm on the 100 mm Visual Analog Scale (VAS) of the ShortForm McGill Pain Questionnaire (SFMPQ)at the Screening and Baseline Visits. Key History of malignancy or clinically significant (as determined by the Investigator) allergies, cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic (not related to sciatica), dermatologic, rheumatic/joint, psychiatric, renal, and/or other major disease. History of signs or symptoms of peripheral neuropathy, other than symptoms of sciatica. History of severe allergic or anaphylactic drugrelated reactions. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>